Vistagen Therapeutics (VTGN) Net Income towards Common Stockholders (2011 - 2026)
Vistagen Therapeutics' Net Income towards Common Stockholders came in at -$13.03 million for fiscal Q1 2027 (quarter ended Jun 30, 2026), compared with -$15.1 million a year earlier.
Powered by 
Analysis
Vistagen Therapeutics (VTGN) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Vistagen Therapeutics reported Net Income towards Common Stockholders of -$67.62 million; for FY2026 (ended Mar 31, 2026), it was -$69.69 million.
- Going back by fiscal year, Net Income towards Common Stockholders was -$51.42 million in FY2025, -$29.36 million in FY2024, -$59.25 million in FY2023 and -$48.71 million in FY2022.
- The fiscal Q1 2027 figure represents the highest quarterly Net Income towards Common Stockholders since fiscal Q2 2025.
- Business Quant data shows VTGN's Net Income towards Common Stockholders at -$16.27 million (Q4 2026), -$18.9 million (Q3 2026) and -$19.42 million (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 5.53 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 2.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Vistagen Therapeutics | 12.43 Mn | 12.43 Mn | - | -13.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.03 Mn |
| Mar 31, 2026 | -16.27 Mn |
| Dec 31, 2025 | -18.90 Mn |
| Sep 30, 2025 | -19.42 Mn |
| Jun 30, 2025 | -15.10 Mn |
| Mar 31, 2025 | -13.64 Mn |
| Dec 31, 2024 | -14.09 Mn |
| Sep 30, 2024 | -12.96 Mn |
| Jun 30, 2024 | -10.73 Mn |
| Mar 31, 2024 | -9.52 Mn |
| Dec 31, 2023 | -6.35 Mn |
| Sep 30, 2023 | -6.59 Mn |
| Jun 30, 2023 | -6.90 Mn |
| Mar 31, 2023 | -12.23 Mn |
| Dec 31, 2022 | -9.76 Mn |
| Sep 30, 2022 | -17.48 Mn |
| Jun 30, 2022 | -19.78 Mn |
| Mar 31, 2022 | -16.69 Mn |
| Dec 31, 2021 | -10.74 Mn |
| Sep 30, 2021 | -13.17 Mn |
API Access
Vistagen Therapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=VTGN&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "VTGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=VTGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();